This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read RenovoRx’s 8K filing here.
About RenovoRx
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
See Also
- Five stocks we like better than RenovoRx
- Why is the Ex-Dividend Date Significant to Investors?
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Where Do I Find 52-Week Highs and Lows?
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Which Wall Street Analysts are the Most Accurate?
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
